Table 3.

Crude Perioperative and Short‐Term Postoperative Outcomes

Variable	TAVR Group (n=55)	SAVR Group (n=55)	P Value
In‐hospital outcomes
Mortality, n (%)	1 (1.8)	2 (3.6)	1.00
MI, n (%)	0 (0.0)	1 (1.8)	1.00
Stroke, n (%)	0 (0.0)	1 (1.8)	1.00
MACE, n (%)	1 (1.8)	2 (3.6)	1.00
Postoperative atrial fibrillation, n (%)	2 (3.6)	18 (32.7) a	<0.001
Permanent pacemaker placement, n (%)	8 (14.5)	4 (7.3)	0.36
Respiratory arrest, n (%)	0 (0.0)	3 (5.5)	0.24
Renal failure requiring dialysis, n (%)	0 (0.0)	2 (3.6)	0.48
Cardiac tamponade, n (%)	0 (0.0)	2 (3.6)b	0.48
VARC‐2 defined life‐threatening or major bleeding, n (%)	0 (0.0)	2 (3.6)b	0.48
Length of hospital stay, d	4.0 (2.0, 5.0)	6.0 (5.0, 8.0)	<0.001
30‐d outcomes
All‐cause mortality, n (%)	1 (1.8)	5 (9.1)c	0.21
30‐d rehospitalization, n (%)	6 (10.9)	3 (5.5)	0.49
1‐y outcomes
All‐cause mortality, n (%)	9 (16.4)	6 (10.9)	0.40
90‐d rehospitalization, n (%)	17 (30.9)	3 (5.5)	0.001

Data are presented as mean±SD, no. (%), or median (Q1, Q3). CABG indicates coronary artery bypass graft; MACE, major adverse cardiac events; MI, myocardial infarction; SAVR, surgical transcatheter aortic valve replacement; TAVR, transcatheter aortic valve replacement; VARC‐2, Valve Associated Research Consortium‐2.

^aFour patients had concomitant SAVR and CABG and developed postoperative atrial fibrillation. The other 14 patients had isolated SAVR.

^bOne patient had concomitant SAVR and CABG and had tamponade and life‐threatening bleeding.

^cTwo patients had concomitant SAVR and CABG; the other 3 had isolated SAVR.